Teva and Fosun Pharma Forge Alliance for Next-Gen Cancer Treatment Development

Teva and Fosun Pharma Establish Strategic Partnership for Cancer Therapy Development

In a noteworthy move, Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical have announced a strategic partnership focused on the development of TEV-56278, an innovative anti-PD1-IL2 ATTENUKINE therapy. The agreement, formalized on June 16, 2025, aims to enhance the clinical data generation process for this promising treatment, which is currently in Phase 1 trials for various cancer types, including melanoma.

At the core of their collaboration is Teva's ATTENUKINE technology, designed to provide a new therapeutic mechanism that aspires to deliver high efficacy with minimal toxicity across multiple oncology indications. By joining forces, Teva and Fosun Pharma intend to leverage their unique strengths, consolidating Teva’s capabilities in innovative drug development with Fosun's extensive experience in oncology within the Chinese market.

Under this agreement, Fosun Pharma has secured an exclusive license to develop, manufacture, and commercialize TEV-56278 across China, Hong Kong, Macau, Taiwan, and selected Southeast Asian countries. Meanwhile, Teva maintains its rights to development and commercialization in all other global markets. This partnership marks a significant advancement in the global strategy for TEV-56278, allowing Teva to utilize clinical data generated by Fosun Pharma in their further efforts around the globe.

Eric Hughes, Executive Vice President of Teva Global R&D and Chief Medical Officer, remarked on the vital importance of such collaborations, stating, "This partnership with Fosun Pharma represents a critical step toward accelerating our pipeline and is a testament to the strength of Teva’s innovative drug development capabilities. The potential impact of TEV-56278 on patient outcomes makes this partnership both timely and important."

The Future of Immuno-Oncology at Teva and Fosun

TEV-56278 operates on a novel principle, combining anti-PD1 antibodies with interleukin-2 (IL-2) to deliver a targeted immunotherapy approach. By focusing on PD-1+ T cells in the tumor microenvironment, this therapy aims to enhance anti-tumor response while minimizing harmful off-target effects. This innovative treatment strategy is particularly critical in the landscape of modern cancer therapies, where the reduction of systemic toxicities remains a paramount concern.

Xingli Wang, CEO of Fosun Pharma’s Global R&D Center, expressed enthusiasm about this partnership: "Joining forces with Teva allows us to harness their innovative prowess in drug development along with our robust capabilities in oncology, effectively accelerating the delivery of this vital therapy to patients on a global scale."

Positive Implications and Goals for TEV-56278

As TEV-56278 undergoes further clinical evaluation, it is expected to play a crucial role in expanding treatment avenues for patients facing challenging cancer diagnoses. Preclinical studies have already showcased promising results, including noticeable tumor regression, increased T-cell infiltration, and the potential for durable immune memory.

With both companies committed to advancing the field of cancer therapy, the partnership between Teva and Fosun Pharma represents a shared vision of improving patient care and expanding therapeutic options. Teva, with its longstanding history in pharmaceuticals, and Fosun, recognized for its innovative approaches and strategic growth in the healthcare sector, look forward to the combined benefits of their collaboration in addressing critical unmet medical needs worldwide.

The collaboration is not merely about business; it reflects a shared commitment to enhancing the health outcomes of patients globally. As the development of TEV-56278 progresses, both companies remain optimistic about its potential to redefine the future of cancer immunotherapy.

About the Organizations

Teva Pharmaceutical Industries Ltd. has a history of over 120 years in the health sector, committed to providing reliable medicines globally. Its diverse portfolio includes both generic and innovative medicines aimed at addressing extensive healthcare needs.

Fosun Pharma, established in 1994, is recognized for its innovation-driven approach in the healthcare sphere and aims to merge pharmaceutical expertise with cutting-edge healthcare services across a global landscape.

In conclusion, the strategic partnership between Teva and Fosun Pharma symbolizes a significant leap forward in the development of innovative cancer treatments, marking a positive stride in the ongoing battle against cancer.